Biomea Fusion Stock Today
| BMEA Stock | USD 1.85 0.03 1.60% |
PerformanceInsignificant
| Odds Of DistressHigh
|
Biomea Fusion is trading at 1.85 as of the 19th of July 2025, a 1.6 percent decrease since the beginning of the trading day. The stock's open price was 1.88. Biomea Fusion has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of April 2021 | Category Healthcare | Classification Health Care |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. The company has 57.02 M outstanding shares of which 8.57 M shares are currently shorted by private and institutional investors with about 3.01 trading days to cover. More on Biomea Fusion
Moving together with Biomea Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Biomea Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBiomea Fusion can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biomea Fusion's financial leverage. It provides some insight into what part of Biomea Fusion's total assets is financed by creditors.
| |||||
Biomea Fusion (BMEA) is traded on NASDAQ Exchange in USA. It is located in 1599 Industrial Road, San Carlos, CA, United States, 94070 and employs 79 people. Biomea Fusion is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 105.49 M. Biomea Fusion conducts business under Biotechnology sector and is part of Health Care industry. The entity has 57.02 M outstanding shares of which 8.57 M shares are currently shorted by private and institutional investors with about 3.01 trading days to cover.
Biomea Fusion currently holds about 149.63 M in cash with (119.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Biomea Fusion Probability Of Bankruptcy
Ownership AllocationBiomea Fusion holds a total of 57.02 Million outstanding shares. 30% of Biomea Fusion outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Biomea Ownership Details
Biomea Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Investments Llc | 2025-03-31 | 472.4 K | |
| Northern Trust Corp | 2025-03-31 | 297.6 K | |
| Millennium Management Llc | 2025-03-31 | 281.7 K | |
| Renaissance Technologies Corp | 2025-03-31 | 278.1 K | |
| Nuveen, Llc | 2025-03-31 | 270.1 K | |
| Aqr Capital Management Llc | 2025-03-31 | 264 K | |
| Woodline Partners Lp | 2025-03-31 | 240.8 K | |
| Ubs Group Ag | 2025-03-31 | 236.9 K | |
| Charles Schwab Investment Management Inc | 2025-03-31 | 181.4 K | |
| Fmr Inc | 2025-03-31 | 5.4 M | |
| Cormorant Asset Management, Llc | 2025-03-31 | 3.6 M |
Biomea Fusion Historical Income Statement
Biomea Stock Against Markets
Biomea Fusion Corporate Management
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Stephan MD | Chief Officer | Profile | |
| Franco Valle | CFO Officer | Profile | |
| Ravi Upasani | Executive Property | Profile | |
| Ramses Erdtmann | President, CoFounder | Profile | |
| Thomas Butler | Chairman CoFounder | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.